News and Announcements
H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB
- Published November 30, 2015 12:20PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th November 2015, ASX Announcement
Clinical stage oncology company Prescient Therapeutics Ltd (PTX) is delighted to announce the appointment of the H. Lee Moffitt Cancer Center’s Professor Jeffrey Lancet MD to PTX’s Scientific Advisory Board (SAB).
Professor Lancet is a medical oncologist whose work involves the development and implementation of clinical trials using small molecule inhibitors in acute leukemias.
This is of particular interest to PTX ahead of an upcoming clinical trial in Acute Myeloid Leukemia (AML) in early 2016.
Professor Lancet was an investigator on PTX’s earlier Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Center in 32 patients with advanced haematologic malignancies.
To read the full announcement, please click here.